Learn about 3 patients in the ERIVANCE trial and why they were deemed eligible for treatment with Erivedge® (vismodegib)

Erivedge was studied in ERIVANCE, a pivotal trial1,2

ERIVANCE was a Phase II, international, single-arm, 2-cohort, open-label trial that demonstrated clinically meaningful benefit in advanced basal cell carcinoma (BCC). The trial was conducted in 104 patients with either metastatic BCC (mBCC) (n=33) or locally advanced BCC (laBCC) (n=71). Of the 104 patients enrolled, 96 were evaluable for objective response rate (ORR) and were treated with Erivedge 150 mg once per day orally until disease progression, intolerable toxicity, or withdrawal from study. Patients were seen at baseline and every 4 weeks for safety monitoring, and every 8 weeks for response assessment.

<table>
<thead>
<tr>
<th>Objective response rate by independent review from ERIVANCE*</th>
<th>Incidence of common adverse reactions (≥10%): Pooled analysis of 4 studies (N=138)3,4</th>
</tr>
</thead>
<tbody>
<tr>
<td>laBCC (n=63)</td>
<td>mBCC (n=33)</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>ORR</td>
<td>43% (n=27)</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(30.5-56.0)</td>
</tr>
<tr>
<td>Complete response</td>
<td>21% (n=13)</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(15.6-48.2)</td>
</tr>
<tr>
<td>Partial response</td>
<td>22% (n=14)</td>
</tr>
<tr>
<td>Median duration of response (months)</td>
<td>7.6</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(5.7-9.7)</td>
</tr>
<tr>
<td>Loss of taste (ageusia)</td>
<td>8.0%</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(5.6-NE)</td>
</tr>
<tr>
<td>Arthralgias</td>
<td>11.6%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>10.9%</td>
</tr>
</tbody>
</table>

*Patients received at least 1 dose of Erivedge with independent pathologist-confirmed diagnosis of BCC. Locally advanced BCC patients were considered responders if they did not experience progression and had ≥30% reduction in lesion size (sum of the longest diameter) from baseline in target lesions by radiography or in externally visible dimensions of target lesions (scar tissue was measured); or had complete resolution of ulceration in all target lesions. Complete response was objective response with no residual BCC on sampling biopsy. Partial response was objective response with presence of residual BCC on sampling biopsy. In the metastatic BCC cohort, response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Complete response was disappearance of all target and nontarget lesions. Partial response was ≥30% decrease in SLD of target lesions from baseline.

Indication

Erivedge is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.

Boxed Warning

EMBRYO-FETAL TOXICITY

- Erivedge can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. Erivedge is embryotoxic, fetotoxic, and teratogenic in animals. Teratogenic effects included severe midline defects, missing digits, and other irreversible malformations.

Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating Erivedge. Advise pregnant women of the potential risks to a fetus. Advise females of reproductive potential to use effective contraception during and after Erivedge.

Advise males of the potential risk of Erivedge exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential.

Please see full Prescribing Information, including the BOXED WARNING and the Medication Guide, for a complete discussion of the risks associated with Erivedge.
Diane, a 68-year-old with locally advanced BCC

**Diane's history of BCC**
- Diane was initially diagnosed with BCC in 2009
- In 2009, she underwent multiple shave biopsies

**Reasons why patient was deemed eligible for treatment with Erivedge**
- Surgery was medically contraindicated because of anticipated substantial morbidity and/or deformity
- Radiotherapy was considered contraindicated because of multiple morbidities and risk of damage to brain

**Treatment**
- Diane started treatment with Erivedge in September 2009 and was treated for 5.3 months
  - In the ERIVANCE trial, the median duration of treatment was 10.2 months (range, 0.7 to 18.7 months), inclusive of locally advanced BCC and metastatic BCC cohorts
- In March 2010, treatment was discontinued at patient's request

**Clinical outcome**
- Diane experienced a complete response, as assessed by independent review
  - Complete response is defined as objective response with no residual BCC on sampling biopsy
- The sampling biopsy at Week 16 did not show evidence of residual BCC
- Complete response was confirmed at approximately Week 23

**Treatment-related adverse reactions**
- Diane experienced alopecia, dysgeusia, dyspepsia, eye swelling, and muscle spasms

**EMBRYO-FETAL TOXICITY (cont’d)**
- **Females of Reproductive Potential**: Use contraception during therapy with Erivedge and for 24 months after the final dose
- **Males**: Use condoms, even after a vasectomy, to avoid potential drug exposure in pregnant partners and female partners of reproductive potential during and for 3 months after the final dose of Erivedge. Do not donate semen during and for 3 months after the final dose of Erivedge
- **Blood Donation**: Advise patients not to donate blood or blood products while receiving Erivedge and for 24 months after the final dose of Erivedge
- Advise female patients and female partners of male patients to contact their healthcare provider with a known or suspected pregnancy. Report pregnancies to Genentech at (888) 835-2555

Please see full Prescribing Information, including the BOXED WARNING and the Medication Guide, for a complete discussion of the risks associated with Erivedge.
Louis, an 83-year-old with locally advanced BCC

Right and left superior dorsum lateral nose: Infiltrative, nodular, and micronodular BCC

Louis’s history of BCC
- Louis was initially diagnosed with BCC in 2008

Reasons why patient was deemed eligible for treatment with Erivedge
- Surgery was medically contraindicated because of anticipated substantial morbidity and/or deformity
- Radiotherapy was considered contraindicated because of the size of the lesion and proximity to the eyes

Treatment
- Louis started treatment with Erivedge in December 2009 and was treated for 11.1 months
  - In the ERIVANCE trial, the median duration of treatment was 10.2 months (range, 0.7 to 18.7 months), inclusive of locally advanced BCC and metastatic BCC cohorts
- Treatment was discontinued in November 2010 at patient’s request

Clinical outcome
- Louis experienced a non-response, as assessed by independent review
  - Patients were considered non-responders if they met any of the following criteria:
    - <30% decrease in size of target lesions or ≥20% increase in size of target lesions (scar tissue was included in measurement of lesion)
    - New ulceration of lesions persisting without evidence of healing for at least 2 weeks
    - New lesions by radiographic assessment or physical examination
    - Progression of non-target lesions by RECIST*
- The sampling biopsy at Week 24 showed evidence of residual BCC

Treatment-related adverse reactions
- Louis experienced alopecia, decreased appetite, hypogeusia, muscle spasms, and decreased weight
- He had treatment interrupted at least once for up to 4 weeks to manage individual tolerability

*Response Evaluation Criteria in Solid Tumors.

ERIVANCE patient eligibility is based on study investigator assessment. Case study shows results of treatment in a specific patient and case was last verified at clinical data cutoff. Individual results may vary. This case is for general informational purposes only and is not intended to convey medical advice. You should use your independent medical judgment in the diagnosis and treatment of your patients.

Additional Important Safety Information

Premature Fusion of the Epiphyses
- Premature fusion of the epiphyses has been reported in pediatric patients exposed to Erivedge. In some cases, fusion progressed after drug discontinuation. Erivedge is not indicated for pediatric patients

Please see full Prescribing Information, including the BOXED WARNING and the Medication Guide, for a complete discussion of the risks associated with Erivedge.
PARTIAL RESPONDER FROM THE ERIVANCE TRIAL

Frank, a 54-year-old with metastatic BCC

**Frank's history of BCC**
- Frank was initially diagnosed with BCC in 2005
- Frank underwent multiple surgeries (right ear, right mastoid bone, and right temporal bone) and multiple biopsies (right neck node, lung nodule)
- Frank had radiation directed to the right ear canal in 2005
- Frank received treatment for metastatic disease in 2009

**Treatment**
- Frank started treatment with Erivedge in June 2009 and was treated for 9.5 months
  - In the ERIVANCE trial, the median duration of treatment was 10.2 months (range, 0.7 to 18.7 months), inclusive of locally advanced BCC and metastatic BCC cohorts
- In March 2010, treatment was discontinued because of disease progression

**Clinical outcome**
- Frank experienced a partial response, as assessed by independent review
  - Partial response is defined as ≥30% decrease in sum of longest diameter of target lesions from baseline

**Treatment-related adverse reactions**
- Frank experienced alopecia, dysgeusia, muscle spasms, nail disorder, and nausea

**Adverse Reactions**
- The most common adverse reactions (≥10%) were muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, and ageusia
- Amenorrhea can occur in females of reproductive potential. Reversibility of amenorrhea is unknown. In clinical trials, 30% of 10 pre-menopausal women developed amenorrhea while receiving Erivedge
- Grade 3 laboratory abnormalities observed in clinical trials were hyponatremia (4%), azotemia (2%), and hypokalemia (1%)
- Additionally, in a post-approval clinical trial conducted in 1232 patients with locally advanced or metastatic BCC treated with Erivedge, a subset of 29 patients had baseline values for blood creatine phosphokinase (CPK) reported. Within the subset of patients, 38% had a shift from baseline, including Grade 3 (3%) increased CPK. Grade 3 or 4 increased CPK occurred in 2.4% of the 453 patients across the entire study population with any CPK measurement

**Use in Specific Populations**

**Lactation**
- No data are available regarding the presence of vismodegib in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. Advise women that breastfeeding is not recommended during therapy with Erivedge and for 24 months after the final dose

Please see full Prescribing Information, including the BOXED WARNING and the Medication Guide, for a complete discussion of the risks associated with Erivedge.
Do you see patients with advanced BCC in your practice?
Visit Erivedge.com to learn more about Erivedge

Boxed Warning and Additional Important Safety Information

Boxed Warning

**EMBRYO-FETAL TOXICITY**

- Erivedge can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. Erivedge is embryotoxic, fetotoxic, and teratogenic in animals. Teratogenic effects included severe midline defects, missing digits, and other irreversible malformations.
- Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating Erivedge. Advise pregnant women of the potential risks to a fetus. Advise females of reproductive potential to use effective contraception during and after Erivedge.
- Advise males of the potential risk of Erivedge exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential.
- Females of Reproductive Potential: Use contraception during therapy with Erivedge and for 24 months after the final dose.
- Males: Use condoms, even after a vasectomy, to avoid potential drug exposure in pregnant partners and female partners of reproductive potential during and for 3 months after the final dose of Erivedge.
- Blood Donation: Advise patients not to donate blood or blood products while receiving Erivedge and for 24 months after the final dose of Erivedge.
- Advise female patients and female partners of male patients to contact their healthcare provider with a known or suspected pregnancy. Report pregnancies to Genentech at (888) 835-2555.

Additional Important Safety Information

**Premature Fusion of the Epiphyses**

- Premature fusion of the epiphyses has been reported in pediatric patients exposed to Erivedge. In some cases, fusion progressed after drug discontinuation. Erivedge is not indicated for pediatric patients.

**Adverse Reactions**

- The most common adverse reactions (>10%) were muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, and ageusia.
- Amenorrhea can occur in females of reproductive potential. Reversibility of amenorrhea is unknown. In clinical trials, 30% of 10 pre-menopausal women developed amenorrhea while receiving Erivedge.
- Grade 3 laboratory abnormalities observed in clinical trials were hyponatremia (4%), azotemia (2%), and hypokalemia (1%).
- Additionally, in a post-approval clinical trial conducted in 1232 patients with locally advanced or metastatic BCC treated with Erivedge, a subset of 29 patients had baseline values for blood creatine phosphokinase (CPK) reported. Within the subset of patients, 38% had a shift from baseline, including Grade 3 (3%) increased CPK. Grade 3 or 4 increased CPK occurred in 2.4% of the 453 patients across the entire study population with any CPK measurement.

**Use in Specific Populations**

**Lactation**

- No data are available regarding the presence of vismodegib in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. Advise women that breastfeeding is not recommended during therapy with Erivedge and for 24 months after the final dose.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.